J&J calls time on Addex partnership 9 months after dropping failed epilepsy drug
Nine months after Johnson & Johnson stepped back from an Addex Therapeutics-partnered epilepsy drug in the wake of a phase 2 fail, the Big Pharma has now fully severed its relationship with the Swiss biotech.
Nine months after Johnson & Johnson stepped back from an Addex Therapeutics-partnered epilepsy drug in the wake of a phase 2 fail, the Big Pharma has now fully severed its relationship with the Swiss biotech.
